Navigation Links
Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Date:11/13/2011

rimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently being studied in an interferon-free, Phase 3 program (FISSION and POSITRON) and in five Phase 2b trials in subjects with all HCV genotypes. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, is in QUANTUM, a Phase 2b interferon-free trial of PSI-7977 and PSI-938 in subjects with all HCV genotypes. Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 865-0693 Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset to Webcast an Investor Event from the AASLD Meeting
2. Pharmasset to Present at Four Upcoming Investor Conferences
3. Pharmasset to Present at Canaccord Adams Conference
4. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
7. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
8. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
9. Pharmasset to Present at Two Upcoming Investor Conferences
10. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
11. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Appistry, Inc. ... that bring the power of genomics to next-generation medicine, ... Appistry Pipeline Challenge . , Two Appistry staff ... the National Center for Genome Resources, and Mr. Neil ... Clinics of Kansas City. Rounding out the panel are ...
(Date:7/28/2014)... -- Research and Markets has announced the addition ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... used to determine the size of a particle in a ... analyze the size of particles as it can affect the ... to determine the behavior and nature of a material, and ...
(Date:7/25/2014)... Trillions of bacteria live in each person,s digestive tract. ... food and stave off harmful infections, but their role ... help shed light on the role of these bacteria, ... Eric Alm recently tracked fluctuations in the bacterial populations ... findings, described in the July 25 issue of the ...
(Date:7/25/2014)... The Conferee Networking committee is pleased to ... These two-hour sessions provide a unique networking opportunity for ... discuss new techniques, or brainstorm new ideas in an ... for consideration is August 31, 2014, and instructions can ... committee will review the topics, and status notifications will ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2
... THE WOODLANDS, Texas, Oct. 4 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... Ph.D., Lexicon,s president and chief executive officer, will present,at ... Francisco, California,on Thursday, October 11, 2007 at 11:00 a.m. ... may be accessed on its,corporate website at http://www.lexpharma.com ...
... Oct. 4 Genzyme Corp.,(Nasdaq: GENZ ) ... market,Elaprase(R) (idursulfase) in Japan for the treatment of ... by Shire Human Genetic,Therapies Inc., and Genzyme is ... countries under an agreement with Shire. Genzyme intends,to ...
... CLARA, Calif., Oct. 4 Coherent, Inc.,(Nasdaq: COHR ... 2007, it,received an additional NASDAQ Staff Determination letter indicating ... listing,requirements as set forth in Marketplace Rules 4350(e) and ... of stockholders during its fiscal,year ended September 30, 2007. ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Genzyme Receives Approval to Market Elaprase(R) in Japan 2Genzyme Receives Approval to Market Elaprase(R) in Japan 3Genzyme Receives Approval to Market Elaprase(R) in Japan 4Coherent, Inc. Receives Expected Letter from NASDAQ 2
(Date:7/28/2014)... for Biologically Inspired Engineering at Harvard University today ... commercialized by a newly formed private company to ... medicine products. The announcement follows a ... Development (OTD) and the start-up Emulate Inc., relating ... Organs-on-Chips platform. , "This is a big ...
(Date:7/27/2014)... nicotine and cotinine, a metabolite of nicotine, can potentially ... smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is produced ... up in the tobacco smoke. Once inhaled, it is ... activated by a variety of enzymes called Cytochrome P450 ... can partially interfere with the activation of NNK, and ...
(Date:7/27/2014)... mayfly in the southern Western Ghats, a mountain range along ... first time that any mayfly belonging to the genus ... new species, called Labiobaetis soldani , "is named in ... the understanding of the Ephemeroptera of Palaearctic and Oriental realms," ... new mayfly in the Journal of Insect Science . ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... senior female family members should play a key role in ... societies. However, they are often overlooked by health organisations that ... as an obstacle to promoting good nutrition and health practices. ... review published in the January issue of Maternal and ...
... This press release is available in German . ... as tsunamis, landslides, and ground settlements, caused a damage of ... the so far highest economic losses due to earthquakes. This ... from the Center for Disaster Management and Risk Reduction Technology ...
... Springer celebrates its 50,000th eBook, available on ... milestone underscores Springer,s position as the largest eBook ... world,s most comprehensive online collection of science, technology ... In addition, as announced in October 2011, ...
Cached Biology News:Research highlights key role grandmothers play in mother and child nutrition and health 2Research highlights key role grandmothers play in mother and child nutrition and health 3Japan and New Zealand were hit hardest by earthquakes 2SpringerLink now offers more than 50,000 eBooks 2
... The Mini-PROTEAN 3 Dodeca cell with multi-casting ... of up to 12 mini format handcast (8.3 ... cm) gels. The cell requires 3.4-4.4 L of ... cooling coil that attaches to an external refrigerated ...
...
... has been developed to significantly increase the ... Stability is increased at room temperature ... This product is subjected to 0.2 ... azide. This formulation insures consistently high ...
...
Biology Products: